| Title |
Retinal vein occlusion and macular edema – critical evaluation of the clinical value of ranibizumab
|
|---|---|
| Published in |
Clinical Ophthalmology, June 2011
|
| DOI | 10.2147/opth.s13774 |
| Pubmed ID | |
| Authors |
Pearse A Keane, Srinivas R Sadda |
| Abstract |
Retinal vein occlusions (RVOs) constitute the second most common cause of retinal vascular disease after diabetic retinopathy, with a prevalence of between 1% and 2% in persons older than 40 years of age. Despite the existence of numerous potential therapeutic options, none is entirely satisfactory, and many patients with RVO suffer irreversible visual loss. Fortunately however, the recent introduction of antivascular endothelial growth factor (VEGF) agents, such as ranibizumab (Lucentis(®), Genentech, South San Francisco, CA) and bevacizumab (Avastin(®), Genentech), offers a potentially new treatment approach for clinicians managing this disorder. The results of the BRAVO and CRUISE trials have provided the first definitive evidence for the efficacy and safety of ranibizumab in the treatment of RVO. As a result, ranibizumab has recently been approved by the US Food and Drug Administration for the treatment of RVO-associated macular edema. In this review, we provide a critical evaluation of clinical trial data for the safety and efficacy of ranibizumab, and address unresolved issues in the management of this disorder. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 46 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Turkey | 1 | 2% |
| Ireland | 1 | 2% |
| United Kingdom | 1 | 2% |
| Canada | 1 | 2% |
| Mexico | 1 | 2% |
| Unknown | 41 | 89% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 9 | 20% |
| Researcher | 8 | 17% |
| Student > Postgraduate | 5 | 11% |
| Other | 4 | 9% |
| Professor > Associate Professor | 4 | 9% |
| Other | 10 | 22% |
| Unknown | 6 | 13% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 24 | 52% |
| Agricultural and Biological Sciences | 6 | 13% |
| Business, Management and Accounting | 2 | 4% |
| Computer Science | 2 | 4% |
| Social Sciences | 2 | 4% |
| Other | 2 | 4% |
| Unknown | 8 | 17% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 August 2023.
All research outputs
#8,261,756
of 25,373,627 outputs
Outputs from Clinical Ophthalmology
#776
of 3,712 outputs
Outputs of similar age
#43,985
of 122,181 outputs
Outputs of similar age from Clinical Ophthalmology
#11
of 27 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one has received more attention than most of these and is in the 66th percentile.
So far Altmetric has tracked 3,712 research outputs from this source. They receive a mean Attention Score of 4.9. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 122,181 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 62% of its contemporaries.
We're also able to compare this research output to 27 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 59% of its contemporaries.